For more information about Exact Sciences, the company behind the Oncotype DX test, visit
For stories about patients in Canada who have used the Oncotype DX test, visit the
The Breast Recurrence Score test is performed on a post-surgery (lumpectomy or mastectomy) tumour sample or on a core biopsy. As a result, the test should be used after the original surgery or biopsy, but before treatment begins—since the test is intended to help guide treatment decisions. Learn more about how the
If you have ductal carcinoma in situ (DCIS), you have stage 0 (non-invasive) cancer. “In situ” means all of the cancer cells have not spread outside the milk duct. Only patients with DCIS are eligible for
Learn more about the
If the cancer cells in your breast have estrogen receptors, they are called "ER-positive". ER-positive cancer cells (like normal breast cells) may receive signals from estrogen—so the cancer might respond to hormonal therapy. If the cancer cells don’t have estrogen receptors, they are classified as "ER-negative". With ER-negative cancer cells, hormonal treatment is unlikely to work, so your doctor will look for other options.
Only patients with HER2-negative (HER2-) status are eligible for the
Wellspring
